Worldwide Webinar Series:

Impact of Modeling & Simulation in Drug Development

Rosa’s Worldwide Webinar Series fosters the adoption of modeling and simulation by informing a broad audience about the strategic impact it can have on all aspects of research and development.

Since its inception in 2011, this complimentary monthly series has featured select speakers from academia, industry, Rosa client companies, and Rosa itself. The series has drawn many thousands of attendees worldwide from all drug development disciplines.

PLEASE NOTE - ***ALL WEBINARS PRIOR to 2017*** are available by contacting us CLICK HERE

Sign up to receive Webinar and QSP News Alerts

Date	Presenter / Topic	Register
Dec 09, 2026 09:00 AM - 10:00 AM PACIFIC TIME	Tom Yankeelov, PhD, Professor of Biomedical Engineering and Diagnostic Medicine Tom Yankeelov received an MA in Applied Mathematics and an MS in Physics from Indiana University, before completing the PhD in Biomedical Engineering at SUNY @ Stony Brook. He completed his post-doc at the Vanderbilt University Institute of Imaging Science and climbed the ranks to Full Professor in 2010. He then joined the faculty at The University of Texas at Austin in 2016 where he is now the W. A. “Tex” Moncrief Chair of Computational Oncology and Professor of Biomedical Engineering and Diagnostic Medicine. Dr. Yankeelov is the founding Director of the Center for Computational Oncology, and also serves as co-Director for the Quantitative Oncology Research Program within the UT Austin Cancer Center. He is also an Adjunct Professor of Imaging Physics at MD Anderson Cancer Center. The overall goal of Dr. Yankeelov's research is to develop tumor forecasting methods by integrating advanced imaging technologies with predictive models of tumor growth to optimize therapy on a patient-specific basis. This is accomplished by dividing his time into approximately equal parts mathematical modeling, pre-clinical development, and implementation in clinical trials. These efforts have resulted in 284 scientific publications, nearly 400 conference abstracts, and > 260 presentations at institutions around the world. In 2026, Dr. Yankeelov won the UT President’s Research Impact award. He is also an accomplished classroom teacher, having won the 2025 Friar Centennial Teaching Award at UT Austin. A practical computational platform for systematically investigating alternative treatment schedules for cancer	More Info

Dec 09, 2026 09:00 AM - 10:00 AM PACIFIC TIME

Tom Yankeelov, PhD, Professor of Biomedical Engineering and Diagnostic Medicine
Tom Yankeelov received an MA in Applied Mathematics and an MS in Physics from Indiana University, before completing the PhD in Biomedical Engineering at SUNY @ Stony Brook. He completed his post-doc at the Vanderbilt University Institute of Imaging Science and climbed the ranks to Full Professor in 2010. He then joined the faculty at The University of Texas at Austin in 2016 where he is now the W. A. “Tex” Moncrief Chair of Computational Oncology and Professor of Biomedical Engineering and Diagnostic Medicine. Dr. Yankeelov is the founding Director of the Center for Computational Oncology, and also serves as co-Director for the Quantitative Oncology Research Program within the UT Austin Cancer Center. He is also an Adjunct Professor of Imaging Physics at MD Anderson Cancer Center. The overall goal of Dr. Yankeelov's research is to develop tumor forecasting methods by integrating advanced imaging technologies with predictive models of tumor growth to optimize therapy on a patient-specific basis. This is accomplished by dividing his time into approximately equal parts mathematical modeling, pre-clinical development, and implementation in clinical trials. These efforts have resulted in 284 scientific publications, nearly 400 conference abstracts, and > 260 presentations at institutions around the world. In 2026, Dr. Yankeelov won the UT President’s Research Impact award. He is also an accomplished classroom teacher, having won the 2025 Friar Centennial Teaching Award at UT Austin.

A practical computational platform for systematically investigating alternative treatment schedules for cancer

More Info